Hasil Pencarian - Michael Kurman

  • Menampilkan 1 - 2 hasil dari 2
Perbaiki Hasil
  1. 1
    797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)

    797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (T... oleh Joseph Markowitz, Siqing Fu, Gregory Daniels, Lyudmila Bazhenova, Nikhil Khushalani, Zeynep Eroglu, Andrew Brohl, Heather Yeckes-Rodin, Lori McCormick, Michael Kurman, Mireille Gillings, Gloria Lee

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

    Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma oleh Adrienne A. Phillips, Paul A. Fields, Olivier Hermine, Juan C. Ramos, Brady E. Beltran, Juliana Pereira, Farooq Wandroo, Tatyana Feldman, Graham P. Taylor, Ahmed Sawas, Jeffrey Humphrey, Michael Kurman, Junji Moriya, Karen Dwyer, Mollie Leoni, Kevin Conlon, Lucy Cook, Jason Gonsky, Steven M. Horwitz

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: